600671 Stock Overview
Engages in the pharmaceutical manufacturing and drug distribution businesses in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.46 |
| 52 Week High | CN¥12.41 |
| 52 Week Low | CN¥5.85 |
| Beta | 0.19 |
| 1 Month Change | 6.17% |
| 3 Month Change | 45.99% |
| 1 Year Change | -17.38% |
| 3 Year Change | 11.56% |
| 5 Year Change | -23.09% |
| Change since IPO | 179.15% |
Recent News & Updates
What Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd's (SHSE:600671) 27% Share Price Gain Is Not Telling You
Oct 25
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHSE:600671) Investors Are Less Pessimistic Than Expected
Jul 18Shareholder Returns
| 600671 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.1% | -1.9% | -1.2% |
| 1Y | -17.4% | -1.8% | 11.8% |
Return vs Industry: 600671 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 600671 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 600671 volatility | |
|---|---|
| 600671 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600671 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600671's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 380 | n/a | www.hztmyy.com |
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, as well as Chinese medicine diagnosis and treatment services.
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Fundamentals Summary
| 600671 fundamental statistics | |
|---|---|
| Market cap | CN¥1.15b |
| Earnings (TTM) | -CN¥14.51m |
| Revenue (TTM) | CN¥160.35m |
7.2x
P/S Ratio-79.4x
P/E RatioIs 600671 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600671 income statement (TTM) | |
|---|---|
| Revenue | CN¥160.35m |
| Cost of Revenue | CN¥103.24m |
| Gross Profit | CN¥57.11m |
| Other Expenses | CN¥71.62m |
| Earnings | -CN¥14.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 35.62% |
| Net Profit Margin | -9.05% |
| Debt/Equity Ratio | 154.8% |
How did 600671 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|